Defining "Evidence Generation" Within Modern Clinical Trials

By Colin Weller, General Manager, Platform and Digital Solutions

In the clinical research industry, tools like Digital Biomarkers and Endpoints are transforming evidence generation. A recent NIH-published study highlights the regulatory qualification of a digital measure of ambulation, SV95C, setting a crucial precedent for wearable technology in Duchenne Muscular Dystrophy trials. This qualification may reduce sample sizes by up to 70%, positively impacting cost, timelines, insights, and compliance. The potential to cut patient recruitment durations addresses a leading cause of trial delays, mitigating revenue loss and reducing the burden on participants in drug development and clinical research.

Our platform, centered on enabling clinical trial sponsors to gather data and generate evidence, stands out for its unique flexibility, purpose, and structure, with clients noting that they appreciate the adaptability in deploying standard solutions tailored to their trials, fostering participant engagement regardless of location. Learn more about how this distinctive approach, coupled with choice and flexibility, ensures a user-friendly, scalable platform successful in acquiring diverse data.